Why the study?
The balance between thrombotic and bleeding risk is of great concern in high bleeding risk (HBR) patients undergoing PCI.
Does high platelet reactivity increase the risk of thrombotic and bleeding events in high bleeding risk patients undergoing PCI?
Does high platelet reactivity increase the risk of thrombotic and bleeding events in high bleeding risk patients undergoing PCI?
High platelet reactivity is an independent predictor of thrombotic and ischemic events, but not bleeding events, in high bleeding risk patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
HPR signals higher ischemic risk without excess bleeding in HBR PCI patients; hypothesis-generating and requires randomized confirmation before guiding therapy.
BACKGROUND: The balance between thrombotic and bleeding risk is of great concern in high bleeding risk (HBR) patients. This study evaluated the relationship between perioperative antiplatelet reactivity and thrombotic and bleeding events in patients at HBR undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: reaction unit [PRU] >208) or non-HPR (PRU ≤208). Cumulative incidences of cardiovascular and cerebrovascular events (Journal of the American College of Cardiology expert definitions) and bleeding events (Bleeding Academic Research Consortium criteria) were assessed 12 months after index PCI. The incidence of ischemic and bleeding events was ~3-fold higher in HBR vs. non-HBR patients. Thrombotic/ischemic events were significantly more common in the HPR subgroup in HBR patients (hazard ratio [HR]: 1.59; 95% confidence interval [CI]: 1.11-2.28; P=0.012), but there was no difference in non-HBR patients. After adjustment for covariates, HPR in HBR patients remained an independent factor for thrombotic and ischemic events (HR: 1.69; 95% CI: 1.13-2.54; P=0.011), but not for bleeding events (HR: 1.56; 95% CI: 0.78-3.11; P=0.210). CONCLUSIONS: Maintaining adequate PRU levels during PCI is an important factor in improving clinical outcomes, especially for HBR patients.
No takes yet. Share an insight, caveat, or question.
Iijima et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: